Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

NCT ID: NCT03816956

Last Updated: 2023-07-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 174 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-03
• Study Completion Date: 2022-10-28

Brief Summary

AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.

Detailed Description

This study is an international, multicenter, prospective, randomized, double blind, placebo controlled, parallel design protocol in patients with Ventilator-Associated Pneumonia (VAP) caused by S. aureus.

Patients with a documented diagnosis of pneumonia due to S. aureus, and require ICU care, who have been intubated (or have a tracheostomy tube in place) and mechanically ventilated for at least 48 hours are eligible for screening.

In total, approximately 240 subjects will be randomized 1-1 to be treated with placebo plus standard of care (SOC) or AR-301 (20 mg/kg) plus SOC in this Phase 3 study.

Study subjects will receive a single dose at Day 0 in addition to SOC antibiotic treatment, and then enter a safety, efficacy and PK study period for a total study duration of 28 days. The selection of SOC antibiotics is made in accordance with local best practices at the discretion of the investigator.

Conditions

Lung Infection; Pneumonia, Ventilator-Associated; Infection, Bacterial; Staphylococcus Aureus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Study treatment

Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously on the day of randomization.

Group Type: EXPERIMENTAL

AR-301

Intervention Type: DRUG

AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.

Placebo treatment

Control group: Placebo administered intravenously on the day of randomization.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo comparator

Interventions

AR-301

AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.

Intervention Type: DRUG

Placebo

Placebo comparator

Intervention Type: OTHER

Other Intervention Names

AR-301 (tosatoxumab)

Eligibility Criteria

Inclusion Criteria

1. Written Informed Consent given by the patient or, if not possible, by a legally acceptable representative and/or an independent physician as authorized by the competent ethics committee (EC) or independent review board (IRB) and local regulations.

2. To be at least 18 years of age. Taiwan only: To be at least 20 years of age. South Korea only: To be at least 19 years of age.

3. Treated in an ICU at the time of enrollment.

4. Endotracheal tube in place (tracheostomy is allowed).

5. The patient is mechanically ventilated for at least 48 hours.

6. Diagnosis of pneumonia based on the following criteria (a, b, and c, all must be met):

1. One definitive chest X-ray diagnostic of pneumonia within 48 hours,

2. Hypoxemia based on PaO2/FiO2.

3. At least one of the following signs:

i. Documented fever (e.g., body temperature greater than or equal to 38º Celsius).

ii. Hypothermia (e.g., core body temperature less than or equal to 35º Celsius).

iii. Total peripheral white blood cell (WBC) count greater than or equal to 10,000 cells/µL (or mm3).

iv. Leukopenia with total WBC less than or equal to 4,500 cells/µL (mm3). v. Greater than 15 percent immature neutrophils (bands) noted on peripheral blood smear.

7. Documented pulmonary infection with Staphylococcus aureus obtained by bronchoalveolar lavage (BAL), mini-BAL, protected endotracheal aspiration/aspirate (ETA) (collectively 'airway specimen').

Exclusion Criteria

1. The subject is unlikely to survive for the study duration despite delivery of adequate antibiotics and supportive care for treatment of S. aureus pneumonia.

2. Effective antibacterial drug therapy for the index pneumonia administered continuously for 48 hours or more prior to initiation of study treatment. Effective antibiotics would include those typically used to treat S. aureus.

3. Plasmapheresis (ongoing or planned), extracorporeal membrane oxygenation (ECMO) or any procedure that would remove/filter out the monoclonal antibody/study drug.

4. Immunocompromised patients.

5. Known hereditary complement deficiency.

6. Liver dysfunction with a Child Pugh C score > 9 (Child Pugh score of A or B are acceptable at discretion of the Principal Investigator [PI]).

7. Pulmonary disease that precludes evaluation of a therapeutic response (such as lung cancer resulting in bronchial obstruction or on the same side as the pneumonia, active tuberculosis, cystic fibrosis, granulomatous disease, fungal pulmonary infection, lung abscess, pleural empyema or post obstructive pneumonia).

8. Patient has received intravenous (IV) immunoglobulin therapy within 3 months prior to the Screening Visit.

9. Any woman of child-bearing potential (WOCBP) who does not have a negative pregnancy test result at Screening using SERUM or URINE testing based on Beta-subunit human chorionic gonadotropin (HCG) standard tests and methods from the local laboratory.

10. Any sexually active subject who is unwilling to use acceptable methods of contraception for 120 days after dosing.

11. Known lack of treatment compliance from prior studies or ongoing medical care based on medical records and PI's judgment and/or the capacity of the patient to comply with all study requirements.

12. Any medical, psychological, cognitive, social or legal conditions that would interfere in the ability to give an Informed Consent OR the absence of a legally valid representative of the patient or independent physician allowed and able to give consent on his/her behalf.

13. Participation as a subject in another interventional study within 30 days prior to the first dose of study treatment, or planned participation in such a study during the study or within 30 days of its completion by the patient.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aridis Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hasan S Jafri, MD, FAAP

Role: STUDY_DIRECTOR

Aridis Pharmaceuticals

Locations

BLR-06

Grodno, , Belarus

BLR-04

Homyel, , Belarus

BLR-01

Minsk, , Belarus

BEL-01

Lodelinsart, , Belgium

BEL-05

Ottignies, , Belgium

BRA-08

Curitiba, , Brazil

BRA-04

Curitiba, , Brazil

CHN-09

Guangzhou, Guangdong, China

EST-01

Tallinn, , Estonia

FRA-02

Strasbourg, Cedex, France

FRA-18

Brive-la-Gaillarde, , France

FRA-10

Bron, , France

FRA-05

La Roche-sur-Yon, , France

FRA-04

Limoges, , France

FRA-01

Nantes, , France

FRA-16

Orléans, , France

FRA-11

Rennes, , France

FRA-13

Trévenans, , France

GEO-06

Gori, , Georgia

GEO-01

Kutaisi, , Georgia

GEO-03

Kutaisi, , Georgia

GEO-04

Kutaisi, , Georgia

GEO-10

Kutaisi, , Georgia

GEO-02

Tbilisi, , Georgia

GEO-09

Tbilisi, , Georgia

GEO-07

Tbilisi, , Georgia

ISR-04

Haifa, , Israel

ISR-01

Ramat Gan, , Israel

LVA-02

Riga, , Latvia

MEX-07

Guadalajara, Jalisco, Mexico

RUS-18

Arkhangelsk, , Russia

RUS-11

Chelyabinsk, , Russia

RUS-01

Krasnoyarsk, , Russia

RUS-04

Novosibirsk, , Russia

RUS-02

Saint Petersburg, , Russia

RUS-10

Smolensk, , Russia

RUS-16

Zhukovskiy, , Russia

ZAF-09

Johannesburg, , South Africa

ESP-01

Madrid, , Spain

TUR-06

Istanbul, , Turkey (Türkiye)

TUR-01

Trabzon, , Turkey (Türkiye)

UKR-05

Chernivtsi, , Ukraine

UKR-03

Ivano-Frankivsk, , Ukraine

UKR-02

Kharkiv, , Ukraine

UKR-09

Kharkiv, , Ukraine

Countries

Belarus; Belgium; Brazil; China; Estonia; France; Georgia; Israel; Latvia; Mexico; Russia; South Africa; Spain; Turkey (Türkiye); Ukraine

Related Links

https://www.aridispharma.com/contact-us/

Website of the Sponsor

Other Identifiers

AR-301-002

Identifier Type: -

Identifier Source: org_study_id